Scott Isaacs, MD
Endocrinology, Diabetes & Metabolism · Atlanta, GANPI 1700886785
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.0%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 45 manufacturers reported payments, led by Siemens Medical Solutions USA, Inc. at 30.8% of the total. Reporting peaked in 2022 at $4,974 and has fallen 68.8% since, to $1,553 in 2025.
Across 197 payments — averaging $59.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Siemens Medical Solutions USA, Inc.$4K
- Currax Pharmaceuticals LLC$2K
- Novo Nordisk$2K
- Medtronic$695
- Madrigal Pharmaceuticals$649
- Amgen$603
- plus $3K from 39 others
What the payments were for
- Consulting fees$2,50021%
- Speaking & faculty fees$1,87016%
- Travel & lodging$1,61114%
- Food & beverage$5,76949%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CONTRAVE$1,870
- ADVIA Centaur XP Analyzer$335
- REZDIFFRA$327
- MINIMED 780G$284
- RESMETIROM$142
- INPEN SMART INSULIN DELIVERY SYSTEM$136
- Enlite Sensor$120
- MOUNJARO$113
- FREESTYLE LIBRE 3$109
- TEPEZZA$102
How this compares
$11,764 in reported general payments places this provider in the 85th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 39 | $59,859 |
| FarxigaDapagliflozin Propanediol | 75 | $59,442 |
| MounjaroTirzepatide | 41 | $46,115 |
| JardianceEmpagliflozin | 38 | $35,538 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $32,373 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 18 | $16,147 |
| JanuviaSitagliptin Phosphate | 19 | $16,029 |
| TrulicityDulaglutide | 14 | $15,219 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $14,754 |
| RybelsusSemaglutide | 12 | $14,482 |
| Novolog FlexpenInsulin Aspart | 27 | $11,087 |
| SynthroidLevothyroxine Sodium | 42 | $3,838 |
| Humalog Kwikpen U-100Insulin Lispro | 14 | $3,387 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $2,490 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 21 | $2,352 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,515 | $74,34051 claims |
| Lilly USA, LLCMounjaro, Trulicity | $518 | $61,33355 claims |
| AstraZenecaFarxiga | $75 | $59,44275 claims |
| Boehringer IngelheimJardiance | $309 | $35,53838 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $78 | $1,233148 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Atlanta
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Jonathan OwnbyAtlanta$291K
- Gulliermo UmpierrezAtlanta$63K
- Francisco PasquelAtlanta$40K
- Norman WelchAtlanta$25K
- Rachel DerrAtlanta$18K
- Kate WheelerAtlanta$17K
- John ZoraAtlanta$16K
- Ernest BeasleyAtlanta$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.